KR20080110681A - 안정적 에멀젼 조제물 - Google Patents

안정적 에멀젼 조제물 Download PDF

Info

Publication number
KR20080110681A
KR20080110681A KR1020087027937A KR20087027937A KR20080110681A KR 20080110681 A KR20080110681 A KR 20080110681A KR 1020087027937 A KR1020087027937 A KR 1020087027937A KR 20087027937 A KR20087027937 A KR 20087027937A KR 20080110681 A KR20080110681 A KR 20080110681A
Authority
KR
South Korea
Prior art keywords
alkyl
acid
calcium
oil
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020087027937A
Other languages
English (en)
Korean (ko)
Inventor
아누라다 고어
앤 나브라틸
세샤드리 니르반난
크리스토퍼 더블유. 스판케이크
로제 자농
Original Assignee
암겐 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 암겐 인코포레이티드 filed Critical 암겐 인코포레이티드
Publication of KR20080110681A publication Critical patent/KR20080110681A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020087027937A 2006-04-20 2007-04-20 안정적 에멀젼 조제물 Withdrawn KR20080110681A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79382506P 2006-04-20 2006-04-20
US60/793,825 2006-04-20

Publications (1)

Publication Number Publication Date
KR20080110681A true KR20080110681A (ko) 2008-12-18

Family

ID=38537687

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087027937A Withdrawn KR20080110681A (ko) 2006-04-20 2007-04-20 안정적 에멀젼 조제물

Country Status (14)

Country Link
US (1) US8779004B2 (https=)
EP (1) EP2010150A2 (https=)
JP (1) JP5199239B2 (https=)
KR (1) KR20080110681A (https=)
CN (1) CN101437490A (https=)
AU (1) AU2007240317B2 (https=)
BR (1) BRPI0710814A2 (https=)
CA (1) CA2648939C (https=)
CR (1) CR10384A (https=)
EA (1) EA200802166A1 (https=)
MX (1) MX2008013339A (https=)
NO (1) NO20084368L (https=)
WO (1) WO2007124465A2 (https=)
ZA (1) ZA200808773B (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013082427A1 (en) * 2011-11-30 2013-06-06 3M Innovative Properties Company Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same
WO2014142517A1 (ko) * 2013-03-12 2014-09-18 주식회사 아리바이오 라이소포스파티딜콜린 또는 이의 유도체를 포함하는 지질나노물질 및 이의 제조방법
WO2017122881A1 (ko) * 2016-01-12 2017-07-20 (주)노터스생명과학 포스파티딜콜린을 유효성분으로 포함하는 신장질환 예방 또는 치료용 약학 조성물
KR20170132566A (ko) * 2016-05-24 2017-12-04 주식회사 고려비엔피 항생제의 서방형 수의학적 조성물 및 이의 제조방법
KR20200036143A (ko) * 2018-09-27 2020-04-07 한국화학연구원 자가미세유화 약물전달시스템을 이용한 난용성 약물의 약학적 제제

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2928387A1 (en) 2004-05-03 2005-11-17 Merrimack Pharmaceuticals, Inc. Drug delivery liposomes containing anionic polyols or anionic sugars
WO2008008650A1 (en) * 2006-07-10 2008-01-17 Indiana University Research And Technology Corporation Methods for treating cystic kidney diseases
WO2008075173A2 (en) * 2006-12-15 2008-06-26 Ruprecht-Karls-Universität Heidelberg Methods for treating podocyte-related disorders
CA2681582C (en) 2007-03-30 2015-07-14 Amgen Inc. Methods of treating bowel disorders
US8609655B2 (en) * 2008-03-28 2013-12-17 Amgen Inc. Calcimimetic compound for use in the treatment of epithelial injury
JP5468221B2 (ja) * 2008-08-04 2014-04-09 株式会社 メドレックス 難溶性薬物の静注用分散製剤
WO2010042642A1 (en) * 2008-10-08 2010-04-15 Amgen Inc. Calcium receptor modulating agents
US9012511B2 (en) * 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
US9468638B2 (en) * 2010-09-24 2016-10-18 Texas Southern University Itraconazole formulations
US8658676B2 (en) * 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
US20120213855A1 (en) * 2011-02-17 2012-08-23 Cima Labs Inc. Dosage forms for weakly ionizable compounds
ES2611787T3 (es) * 2012-06-07 2017-05-10 Cargill, Incorporated Composiciones de grasa bombeables, utilización en alimento para animales y método para reducir su viscosidad
US9212209B2 (en) * 2012-07-13 2015-12-15 Indiana University Research And Technology Corporation Screening methods for spinal muscular atrophy
CN102895187B (zh) * 2012-09-13 2015-05-06 西安力邦制药有限公司 注射用本芴醇脂肪乳的制备及其在疟疾治疗中的应用
CA2888843C (en) * 2012-10-24 2021-02-23 Cargill, Incorporated Phospholipid-containing emulsifier composition
CN103142477B (zh) * 2013-04-08 2015-09-30 薛巍 一种缓释秋水仙碱的含纳米载体微乳制剂的制备方法
FI3834824T3 (fi) 2014-03-28 2025-12-05 Univ Duke Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla
EP3199150A4 (en) * 2014-09-25 2017-08-09 Fujifilm Corporation Propofol-containing oil-in-water emulsion composition and method for producing same
JP7019422B2 (ja) 2015-04-29 2022-02-15 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法
MX382522B (es) 2015-10-16 2025-03-13 Ipsen Biopharm Ltd Composiciones farmaceuticas estabilizantes de camptotecina.
CN105769765A (zh) * 2016-03-22 2016-07-20 辅必成（上海）医药科技有限公司 己酸羟孕酮脂肪乳注射液
KR102707399B1 (ko) 2017-01-05 2024-09-13 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
CN109200024A (zh) * 2017-07-07 2019-01-15 江苏恒瑞医药股份有限公司 西那卡塞药物组合物及其医药用途
CN109953979A (zh) * 2017-12-25 2019-07-02 江苏恒瑞医药股份有限公司 西那卡塞药物组合物及其医药用途
IL279853B2 (en) 2018-07-04 2025-01-01 Radius Pharmaceuticals Inc Polymorphic forms of RAD 1901-2HCL
JP2022536222A (ja) * 2018-11-02 2022-08-15 アンパサンド バイオファーマシューティカルズ インコーポレイテッド 局所的に施用される緩衝液によるカチオン過負荷および電解質平衡異常のリスクの管理
CN113348163B (zh) 2019-02-12 2024-10-08 雷迪厄斯制药公司 方法和化合物
US11992483B2 (en) 2021-03-31 2024-05-28 Cali Biosciences Us, Llc Emulsions for local anesthetics
CN115554261A (zh) * 2021-07-02 2023-01-03 杭州中美华东制药有限公司 一种包含西那卡塞的组合物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR511940A (fr) 1916-12-08 1921-01-07 Rene Emile Trottier Dispositif pour la commande des appareils destinés au classement ou à la séparation des matières solides de tous genres
JPS60258110A (ja) * 1984-06-05 1985-12-20 Daigo Eiyou Kagaku Kk 静脈注射可能なプロゲステロン乳化注射液
US6001884A (en) 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5763569A (en) 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US5688938A (en) 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5858684A (en) 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
RU2147574C1 (ru) 1991-08-23 2000-04-20 Эн-Пи-Эс Фармасьютикалз, Инк. Арилалкиламины, композиции, способы лечения и диагностики, способы идентификации соединения
CN1192011C (zh) 1991-08-23 2005-03-09 Nps药物有限公司 对钙受体具活性的芳烷基胺化合物
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5962314A (en) 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
EP0637237B1 (en) 1993-02-23 2004-05-19 Brigham And Women's Hospital, Inc. Calcium receptor-active molecules
US6211244B1 (en) 1994-10-21 2001-04-03 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
EP1258471B1 (en) 1996-05-01 2007-01-24 Nps Pharmaceuticals, Inc. Inorganic ion receptor-active compounds
EP0907631B1 (en) 1996-05-01 2003-06-18 Nps Pharmaceuticals, Inc. Inorganic ion receptor-active compounds
US6362231B1 (en) 1996-07-08 2002-03-26 Nps Pharmaceuticals, Inc. Calcium receptor active compounds
TW483881B (en) 1996-12-03 2002-04-21 Nps Pharma Inc Calcilytic compounds
EP2198854B1 (en) 1997-09-18 2011-11-30 Pacira Pharmaceuticals, Inc. Sustained-release liposomal anesthetic compositions
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
ES2211151T3 (es) 1998-08-19 2004-07-01 Skyepharma Canada Inc. Dispersiones acuosas inyectables de propofol.
AU760889B2 (en) 1998-10-14 2003-05-22 Ortho-Mcneil Pharmaceutical, Inc. 1,2-disubstituted cyclopropanes
FR2800735B1 (fr) 1999-11-09 2002-02-01 Centre Nat Rech Scient Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
EP2036540A3 (en) 2000-06-16 2009-12-16 Jagotec AG Improved injectable dispersions of propofol
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
DE60136187D1 (de) 2000-08-11 2008-11-27 Japan Tobacco Inc Calciumrezeptor-antagonisten
FR2820136A1 (fr) 2001-01-26 2002-08-02 Aventis Pharma Sa Nouveaux derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US7176322B2 (en) * 2002-05-23 2007-02-13 Amgen Inc. Calcium receptor modulating agents
KR101050700B1 (ko) 2002-08-26 2011-07-20 다케다 야쿠힌 고교 가부시키가이샤 칼슘 수용체 조절 화합물 및 이의 용도
US20050101576A1 (en) 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
AU2003289163A1 (en) * 2002-12-06 2004-06-30 Otsuka Pharmaceutical Factory, Inc. Propofol-containing fat emulsions
DK1619180T3 (da) 2003-04-23 2010-03-29 Japan Tobacco Inc CaSR-antagonist
CN1225242C (zh) 2003-05-21 2005-11-02 浙江天皇药业有限公司 一种抗肿瘤药物毛兰素脂肪乳剂及其制备方法
WO2004106280A1 (ja) 2003-05-28 2004-12-09 Japan Tobacco Inc. ＣａＳＲアンタゴニスト
DK1648413T3 (da) * 2003-07-23 2010-01-11 Theravance Inc Farmaceutiske præparater af kortvirkende sedativt sövndyssende middel
US20060276534A1 (en) 2005-03-17 2006-12-07 Amgen Inc. Methods of decreasing calcification
FR2885129B1 (fr) 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
WO2006123725A1 (ja) 2005-05-19 2006-11-23 Astellas Pharma Inc. ピロリジン誘導体またはその塩
ES2400693T3 (es) 2005-09-02 2013-04-11 Amgen Inc. Regulación del equilibrio de fluido intestinal usando calcimiméticos
WO2008075173A2 (en) 2006-12-15 2008-06-26 Ruprecht-Karls-Universität Heidelberg Methods for treating podocyte-related disorders

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013082427A1 (en) * 2011-11-30 2013-06-06 3M Innovative Properties Company Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same
US9623087B2 (en) 2011-11-30 2017-04-18 3M Innovative Properties Company Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same
US9675675B2 (en) 2011-11-30 2017-06-13 3M Innovative Properties Company Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same
US10154957B2 (en) 2011-11-30 2018-12-18 3M Innovative Properties Company Microneedle device having a peptide therapeutic agent and an amino acid and methods of making and using the same
WO2014142517A1 (ko) * 2013-03-12 2014-09-18 주식회사 아리바이오 라이소포스파티딜콜린 또는 이의 유도체를 포함하는 지질나노물질 및 이의 제조방법
US10265333B2 (en) 2013-03-12 2019-04-23 Aribio Co., Ltd. Lipid nanomaterial containing lysophosphatidylcholine or derivative thereof and method for preparing same
WO2017122881A1 (ko) * 2016-01-12 2017-07-20 (주)노터스생명과학 포스파티딜콜린을 유효성분으로 포함하는 신장질환 예방 또는 치료용 약학 조성물
KR20170132566A (ko) * 2016-05-24 2017-12-04 주식회사 고려비엔피 항생제의 서방형 수의학적 조성물 및 이의 제조방법
KR20200036143A (ko) * 2018-09-27 2020-04-07 한국화학연구원 자가미세유화 약물전달시스템을 이용한 난용성 약물의 약학적 제제

Also Published As

Publication number Publication date
EA200802166A1 (ru) 2009-06-30
AU2007240317A1 (en) 2007-11-01
WO2007124465A2 (en) 2007-11-01
CA2648939A1 (en) 2007-11-01
JP5199239B2 (ja) 2013-05-15
NO20084368L (no) 2008-11-17
AU2007240317B2 (en) 2012-11-29
BRPI0710814A2 (pt) 2011-08-16
US20070249520A1 (en) 2007-10-25
ZA200808773B (en) 2009-07-29
MX2008013339A (es) 2009-01-26
CR10384A (es) 2008-11-11
EP2010150A2 (en) 2009-01-07
WO2007124465A3 (en) 2008-04-10
JP2009534425A (ja) 2009-09-24
CN101437490A (zh) 2009-05-20
US8779004B2 (en) 2014-07-15
CA2648939C (en) 2014-07-08

Similar Documents

Publication Publication Date Title
US8779004B2 (en) Stable emulsion formulations
RU2642234C2 (ru) Композиции антагонистов нейрокинина-1 для внутривенного введения
RU2678433C2 (ru) Депо-составы гидрофобного активного ингредиента и способы их получения
RU2390331C2 (ru) Жидкие депо-препараты
RU2632433C2 (ru) Липидный преконцентрат с замедленным высвобождением фармакологически активного вещества и фармацевтическая композиция, содержащая его
KR101267901B1 (ko) 프로스타글란딘 ｅ₁을 포함하는 에멀션 조성물
KR102924306B1 (ko) 건강관리 제품을 위한 계면활성제
JP4384409B2 (ja) バイオアベイラビリティが増加したフェンレチニドの医薬組成物、およびその使用方法
BRPI0707421A2 (pt) composições farmaceuticas de succinato de vitamina e estabilizada, métodos para sua preparação e uso
MX2013002005A (es) Dispositivo de fosfolipidos.
KR20140105527A (ko) 강력한 방출-조절된 펩티드 제형
JP7457727B2 (ja) 徐放性脂質前製剤およびそれを含む脂質溶液の形態の徐放性注射用医薬組成物
KR102771577B1 (ko) 3α-에티닐-3β-하이드록시안드로스탄-17-온 옥심의 약학적 제형
US5677341A (en) Emulsion suitable for administering a sphingolipid
DE60225154T2 (de) Neues selbstemulgierendes arzneimittelfreisetzungssystem

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20081114

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid